Calidi Biotherapeutics Presented New CLD-401 Data and In Situ TCE Platform Advances at the ESMO Congress 2026, Including Highlighting the Potential of its RedTail Gene Medicine Platform to Turn Tumors into Localized TCE Biofactories
Calidi Biotherapeutics presented two posters at ESMO 2026 showcasing new preclinical data from its RedTail virotherapy platform, including lead program CLD-401 and its In Situ T-cell engager candidates CLD-501 and CLD-502. CLD-401 induced complete tumor eradication in 80% of mice in an EMT6 breast cancer model versus 0% in controls, and retained antitumor activity via both intravenous and intratumoral delivery in a bladder cancer model. The In Situ TCE data showed approximately 10 ng/mL of EpCAM-targeted T-cell engager produced directly within tumors after IV delivery, addressing systemic-toxicity barriers of conventional TCEs.
Key figures
- Drug Name
- CLD-401
- Phase Of Trial
- Preclinical (IND-enabling studies)
- Tce expression in tumor
- approximately 10 ng/mL
- Complete response rate emt6 model
- 80% of mice
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.